Kadmon (NYSE:KDMN)‘s stock had its “positive” rating restated by investment analysts at Piper Jaffray Companies in a research report issued to clients and investors on Tuesday. They presently have a $9.00 price objective on the stock, up from their prior price objective of $7.00. Piper Jaffray Companies’ price target would indicate a potential upside of 137.47% from the stock’s current price.
Several other equities research analysts have also recently commented on the stock. Jefferies Group boosted their price target on shares of Kadmon to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered shares of Kadmon from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Kadmon in a research note on Friday, December 15th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Kadmon currently has a consensus rating of “Hold” and an average target price of $10.21.
Shares of Kadmon (NYSE:KDMN) opened at $3.79 on Tuesday. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/02/15/kadmon-kdmn-receives-positive-rating-from-piper-jaffray-companies.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.